Compositions of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate(S)-3'-methyl-2' -(pentanoyl{ 2 -(tetrazol-5-ylate)biphenyl-4'-ylmethyl} amino)butyrate]hemipentahydrate

584686 Disclosed is a solid oral dosage form that delivers a therapeutically effective amount of valsartan free acid, or a pharmaceutically acceptable salt thereof comprising: (a) a dual acting compound in a concentration from 4 percent to 90 percent by weight of the composition; and (b) at least on...

Full description

Saved in:
Bibliographic Details
Main Authors AL-FAYOUMI, SULIMAN, KUMARAPERUMAL, NATRAJAN, ZANNOU, ERIKA, AINA, HU, JIAHUI, ROYCE, ALAN, EDWARD, RUEGGER, COLLEEN
Format Patent
LanguageEnglish
Published 28.03.2013
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:584686 Disclosed is a solid oral dosage form that delivers a therapeutically effective amount of valsartan free acid, or a pharmaceutically acceptable salt thereof comprising: (a) a dual acting compound in a concentration from 4 percent to 90 percent by weight of the composition; and (b) at least one pharmaceutically acceptable excipient, wherein the dual acting compound is trisodium [3-((1S,3R)-1-biphenyl-4-yl methyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate-(S)-3'-methyl-2'-(pentanoyl{ 2 -(tetrazol-5-ylate)biphenyl-4'-ylmethyl} amino )butyrate]hemipentahydrate, wherein the dual acting compound is present in an amount of 40, 50, 100, 200 or 400 mg per unit dose.
Bibliography:Application Number: NZ20080584686